A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
This study is testing a new medicine called etavopivat for people living with sickle cell disease. The main goal is to find out if etavopivat can reduce the number of painful events called vaso-occlusive crises (VOCs), which happen when blood vessels get blocked. We also want to see if this medicine can lessen damage to organs, help people exercise more easily, and reduce feelings of tiredness. Half of the participants will receive etavopivat, and the other half will receive a 'dummy pill' (placebo). Who gets which treatment is decided by chance. This study is expected to last for about two years and is part of the ongoing research into etavopivat.
एक नजर में
यह अध्ययन किस बारे में है?
This study is investigating a new medicine called etavopivat for people with sickle cell disease. Sickle cell disease is a lifelong condition that can cause severe pain and other serious health problems. These painful episodes are often called 'crises' or Vaso-occlusive crises (VOCs). They happen when the sickle-shaped red blood cells block small blood vessels, stopping blood from reaching parts of the body. This study wants to see if etavopivat can help reduce how often these painful crises occur.
Beyond reducing pain crises, the research team is also looking at other important aspects of living with sickle cell disease. They want to understand if etavopivat can help protect different organs in the body from the damage that can happen over time with this condition. They will also check if the medicine improves how well people can exercise and whether it reduces the common feeling of extreme tiredness, known as fatigue, that many people with sickle cell disease experience.
Overall, the aim is to confirm if etavopivat is a safe and effective treatment that could improve the lives of adults and teenagers with sickle cell disease. The study will compare etavopivat to a 'placebo', which is a dummy medicine with no active ingredients, to clearly see the effects of the new treatment.
मुख्य निष्कर्ष
- This study is testing a new medicine called etavopivat for sickle cell disease.
- It aims to reduce painful crises, protect organs, and lessen tiredness.
- Participants will receive either etavopivat or a dummy pill (placebo) by chance.
- The study involves regular clinic visits and health checks over about two years.
- If you have sickle cell and are aged 12 or older, you might be able to join.
- आप किसी भी समय भाग लेना बंद कर सकते हैं बिना आपकी चिकित्सा देखभाल पर प्रभाव डाले।.
कौन पात्र हो सकता है?
To join this study, you need to be at least 12 years old, male or female, and have been diagnosed with sickle cell disease. This diagnosis needs to be confirmed by past medical tests like a blood test (haemoglobin electrophoresis or HPLC). You must also have experienced between 1 and 15 painful sickle cell crises (VOCs) in the 12 months before the study starts. These crises need to be recorded in your medical notes, not just remembered.
Your blood test results at the start of the study (called 'screening') also need to show that your haemoglobin levels are somewhere between 5.0 and 10.0 grams per decilitre. This helps ensure that the medicine is being tested in people who fit certain medical criteria for the study.
There are also some reasons why you couldn't take part. For example, if you've had more than 15 painful crises in the last year, or if you're currently having regular blood transfusions. Also, if you use certain other medicines for sickle cell disease, like voxelotor or crizanlizumab, you might not be able to join, or you might need to stop them a certain amount of time before starting the study.
क्या यह अध्ययन आपके लिए उपयुक्त हो सकता है?
यह देखने के लिए इन त्वरित प्रश्नों का उत्तर दें कि क्या आप पात्र हो सकते हैं। यह केवल एक मार्गदर्शिका है — अंतिम निर्णय शोध टीम द्वारा लिया जाता है।.
- क्या आपकी उम्र 12 साल या उससे अधिक है?
- Do you have a confirmed diagnosis of sickle cell disease?
- Have you had between 1 and 15 painful sickle cell crises (VOCs) in the last year, documented by a doctor?
- Are you NOT currently receiving regular, planned blood transfusions?
- Are you NOT currently taking certain other specific sickle cell medicines?
- Is your haemoglobin level, as measured by a doctor, between 5.0 and 10.0 g/dL?
भागीदारी में क्या शामिल है?
If you decide to take part in this study, you'll either receive the new medicine, etavopivat, or a dummy pill (placebo). Which one you get will be decided by chance, like flipping a coin. You won't know which one you're receiving, and neither will your study doctor. This is to make sure the results are fair.
Throughout the study, you'll have regular visits to the clinic where the study team will monitor your health, ask about your symptoms (like pain crises and tiredness), and perform tests. These tests might include blood samples and checks on how well your organs are working. They'll also check your exercise ability. The total study duration is expected to be about two years, involving ongoing treatment and follow-up during this time.
संभावित जोखिम और लाभ
Locations (175)
- Uni of Alabama at Birminghamसत्यापित पोस्टकोडबर्मिंघम, संयुक्त राज्य अमेरिका· भर्ती
- Univer South Alabama Ped/Oncसत्यापित पोस्टकोडमोबाइल, संयुक्त राज्य अमेरिका· भर्ती
- Phoenix Children's Hsptlसत्यापित पोस्टकोडफीनिक्स, संयुक्त राज्य अमेरिका· भर्ती
- आर्कांसस चिल्ड्रन हॉस्पिटलसत्यापित पोस्टकोडलिटिल रॉक, संयुक्त राज्य अमेरिका· भर्ती
- Children's Hospital Los Angeles - Endocrinologyसत्यापित पोस्टकोडलॉस एंजेलेस, संयुक्त राज्य अमेरिका· भर्ती
- UCLA Healthसत्यापित पोस्टकोडलॉस एंजेलेस, संयुक्त राज्य अमेरिका· पूर्ण
- वैली चिल्ड्रन्स हॉस्पिटलसत्यापित पोस्टकोडमडेरा, संयुक्त राज्य अमेरिका· भर्ती
- University Of California Irvineसत्यापित पोस्टकोडऑरेंज, संयुक्त राज्य अमेरिका· पूर्ण
- Stanford University_Palo Altoसत्यापित पोस्टकोडपैलो आल्टो, संयुक्त राज्य अमेरिका· भर्ती
- Harbor-UCLA Medical Centerसत्यापित पोस्टकोडटोरेंस, संयुक्त राज्य अमेरिका· भर्ती
- Clinical and Transl Res Centerसत्यापित पोस्टकोडऑरोरा, संयुक्त राज्य अमेरिका· पूर्ण
- Nemours/AI duPont Hosp-Chldसत्यापित पोस्टकोडविलमिंगटन, संयुक्त राज्य अमेरिका· भर्ती
सामान्य प्रश्न
What is etavopivat?
Etavopivat is a new medicine being tested to see if it helps people with sickle cell disease by possibly reducing painful crises and improving other symptoms.
'प्लेसबो' क्या है?
A placebo is a 'dummy' pill that looks like the study medicine but doesn't contain any active ingredients. It's used to compare the real medicine's effects.
अध्ययन कितने समय तक चलेगा?
The study is expected to last for about two years for each participant.
क्या मुझे पता चलेगा कि मुझे असली दवा मिल रही है या प्लेसीबो?
No, neither you nor your study doctor will know whether you are receiving etavopivat or the placebo. This helps ensure fair and accurate study results.
Will taking part in this study change my regular medical care?
Participating in the study shouldn't stop you from receiving your usual care, but some treatments might need to be paused or adjusted during the study. This will be discussed in detail.
और अधिक जानने के लिए कैसे पता करें
Novo Nordisk
किसी अध्ययन में भाग लेने का निर्णय लेने से पहले हमेशा अपने जीपी या विशेषज्ञ से बात करें।.
भाग लेने में रुचि रखते हैं?
चर्चा
समुदाय चर्चा
हमारे फोरम द्वारा संचालित community.patient.info. कृपया सम्मानजनक रहें — यह चिकित्सा सलाह नहीं है।.